13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Aging and Neurology
Understanding aging and neurology is essential for addressing the neurological challenges that accompany aging. As individuals age, structural changes in the brain can lead to cognitive impairments, motor dysfunctions, and increased susceptibility to neurological diseases. Ongoing research is uncovering the mechanisms behind these changes, including the role of genetic factors, protein accumulation, and disrupted brain plasticity. By exploring new treatments, from neuroprotective drugs to regenerative therapies like stem cell treatments, this field is focused on mitigating the effects of aging on brain health, enhancing the brain’s ability to recover, and improving the overall well-being of older adults. The integration of advanced neuroimaging techniques is also allowing for better understanding of brain aging in real-time, aiding in more precise diagnosis and treatment. These efforts promise to make significant strides in preserving neurological function in older populations.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States